Distinctive Molecular Risk Factors Between MDS and MDS/AML Defined by ICC

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders with a high risk of transformation to acute myeloid leukemia (AML).
• The International Consensus Classification (ICC) defines MDS/AML as MDS with 10%-19% blasts.
• Existing prognostic models like IPSS-M may not accurately stratify risk in MDS/AML due to heterogeneity.

Purpose of the Study:

• To re-evaluate and compare molecular risk factors in MDS (blasts <10%) versus MDS/AML (blasts 10%-19%).
• To develop a new, improved prognostic model for MDS/AML patients.

Main Methods:

• Comparative analysis of molecular landscapes in distinct MDS and MDS/AML cohorts.
• Development and validation of a novel prognostic scoring system, MDS/AML-IPSS-M.

Main Results:

• Significant differences in molecular characteristics were observed between MDS and MDS/AML.
• TP53 aberrations and FLT3-ITD mutations were common risk factors in both groups.
• The new MDS/AML-IPSS-M model demonstrated superior prognostic discrimination compared to existing systems.

Conclusions:

• The molecular biology of MDS and MDS/AML differs significantly, necessitating distinct risk stratification approaches.
• The MDS/AML-IPSS-M model offers improved clinical utility for identifying patients who may benefit from specific therapeutic strategies.
• Findings enhance understanding of MDS progression and aid clinical decision-making.